Core Insights - The cannabis industry is poised for increased profitability as shares of Tilray Brands surged 65% in a week, driven by investor optimism regarding potential regulatory changes from the Trump administration [1][5]. Regulatory Changes - President Trump is reportedly considering reclassifying marijuana from a Schedule I drug to a Schedule III drug, with a decision expected as soon as December 15 [3]. - Schedule I drugs are defined as having no accepted medical use and a high potential for abuse, while Schedule III drugs have moderate to low potential for dependence [4]. Financial Implications - A reclassification could facilitate cannabis companies' access to banking and traditional financial services, and allow them to claim federal tax deductions for business expenses currently disallowed [6]. - This regulatory shift is likely to enhance after-tax profits for Tilray and other cannabis producers, potentially leading to a more lucrative market environment [6].

Core Insights - U.S.-listed cannabis stocks are gaining attention due to potential federal marijuana policy changes, specifically the reclassification of cannabis from Schedule I to Schedule III under the Controlled Substances Act [1][2] - This reclassification could lead to significant federal reforms, easing regulatory pressures, reducing taxes, and attracting institutional capital, which has already resulted in a rally in cannabis equities [2][3] Industry Overview - The potential rollback of Section 280E is a key factor, as it currently prevents cannabis companies from deducting ordinary business expenses, which would improve after-tax profitability and cash flow if reclassified [3] - Better access to banking and capital markets could support valuation expansion for financially disciplined operators [3][4] Company Analysis: Tilray Brands - Tilray Brands (NASDAQ: TLRY) is positioned to benefit from renewed optimism around federal reform, reporting approximately $200 million in revenue, with cannabis contributing nearly half [5] - The company achieved positive adjusted EBITDA of about $13 million and returned to net profitability, ending the quarter with over $400 million in cash and marketable securities [6] - Tilray's valuation is sensitive to regulatory changes, and it serves as a primary entry point for institutional investors, which could lead to accelerated capital inflows upon confirmation of reclassification [7][8] Company Analysis: Canopy Growth - Canopy Growth (NASDAQ: CG) is seen as a leveraged play on U.S. cannabis reform, with a stock rally of over 50% following regulatory news, closing at $1.74 [11] - For Q2 fiscal 2026, Canopy reported approximately $49 million in revenue, with adult-use cannabis revenue increasing by about 30% year-over-year and medical cannabis revenue rising roughly 17% [13] - Although still unprofitable, Canopy's adjusted EBITDA losses are narrowing, and its liquidity position has improved, with cash exceeding total debt by approximately $51 million [14][15]

Fast money trader Tim Seymour. He's behind of course the Amplify Seymour cannabis ETF which surged nearly 55% today. Its best day on record.Such a good day that Tim comes to us in a hoodie. Tim >> in a hoodie. We're talking.Why wouldn't we. Why would I mean the rescheduling that has been something that investors are hoping for. It seems like you get a whiff of it, the stocks go up.You say this is for real this time. Why >> a whiff. No, no pun intended.So I I think it is real. I think it's always been real. ...

Fast money trader Tim Seymour. He's behind of course the Amplify Seymour cannabis ETF which surged nearly 55% today. Its best day on record.Such a good day that Tim comes to us in a hoodie. Tim >> in a hoodie. We're talking.Why wouldn't we. Why would I mean the rescheduling that has been something that investors are hoping for. It seems like you get a whiff of it, the stocks go up.You say this is for real this time. Why >> a whiff. No, no pun intended.So I I think it is real. I think it's always been real. ...

Core Insights - Cannabis stocks experienced a significant surge following the announcement that U.S. President Donald Trump is expected to sign an executive order to ease federal restrictions on marijuana [1][3]. Regulatory Changes - The executive order will reclassify marijuana from a Schedule I substance to Schedule III under the federal Controlled Substances Act, which will alter tax regulations favorably for cannabis companies [2]. - This reclassification is anticipated to facilitate more institutional investment and access to traditional banking services for the cannabis industry, which has been operating in a regulatory grey area [3]. Industry Impact - Analysts believe that the forthcoming executive order could transform the perception of cannabis companies, promoting business growth and signaling the start of a new era in public health policy [4]. - The reclassification is seen as a dismantling of outdated drug policies, aligning more closely with scientific and medical understanding [4]. Investment Opportunities - With cannabis stocks rising, investors are encouraged to explore associated ETFs, including AdvisorShares Pure US Cannabis ETF (MSOS), Roundhill Cannabis ETF (WEED), Amplify Seymour Cannabis ETF (CNBS), Amplify Alternative Harvest ETF (MJ), and AdvisorShares Pure Cannabis ETF (YOLO) [5]. - Following the news, CNBS saw a 35% increase, while the average return of the five ETFs outperformed the broader S&P 500 index by 43% year-to-date [6]. Thematic Investing - Thematic ETFs, including cannabis-focused funds, are showing signs of resurgence and are recommended as complementary growth amplifiers in investors' portfolios [7].

Core Viewpoint - Cannabis stocks experienced a significant surge following reports that President Trump is preparing to reclassify marijuana under federal law, which could ease restrictions and revitalize the industry [1][8]. Industry Impact - The rally represents one of the largest single-day increases for cannabis stocks in years, breaking a prolonged slump that had left many stocks trading at a fraction of their 2021 highs [2][11]. - Reclassifying cannabis from Schedule I to Schedule III under the Controlled Substances Act would acknowledge its medical use and reduce federal barriers that have hindered cannabis companies for years [8][14]. Company Performance - Tilray Brands saw a notable increase, trading at $11.85, up $3.42 or over 40%, although it remains below its 52-week high of $23.20 [4]. - Canopy Growth rose approximately 50% to around $1.70 per share, with trading volume exceeding 117 million shares [5]. - Curaleaf increased by 38% to $3.71 per share, while Aurora Cannabis climbed nearly 18% to about $5.35 per share [5]. Market Indicators - The AdvisorShares Pure US Cannabis ETF, a key indicator for the domestic cannabis industry, jumped more than 50% to around $5.71, nearing its 52-week high of $6.02 after being around $2 earlier this year [5]. - Despite the recent surge, broad cannabis indices remain down over 90% from their pandemic-era peaks, indicating ongoing volatility in the sector [11]. Regulatory Context - Current federal law classifies marijuana as a Schedule I drug, placing it alongside substances like heroin and LSD [6]. - Schedule III status would facilitate medical research, allow cannabis businesses to deduct ordinary expenses, and improve access to banking and institutional capital [9][14]. - Any reclassification would require a rulemaking process involving agencies such as the Drug Enforcement Administration, and no final decisions have been made yet [12]. Investor Sentiment - The sustainability of the recent rally depends on whether Trump will issue a formal order and the speed of regulatory changes [15]. - The surge in cannabis stocks marks a rare moment of optimism for an industry that has faced significant challenges over the past three years [15].

Cannabis stocks are soaring on news that President Trump is looking to reschedule cannabis which would mark a major regulatory milestone for the industry. Most investors appear to be targeting the AdvisorShares Pure US CannabisJulian Lin is a financial analyst. He finds undervalued companies with secular growth that appreciate over time. His approach is to look for companies with strong balance sheets and management teams in sectors with long growth runways. Julian is the leader of the investing group Best ...

Big news in the cannabis world and the markets are lighting up. I'm Brandon Gomez at CNBC headquarters and cannabis stocks today are surging. Why.Well, sources are telling me President Donald Trump could sign an executive order as soon as Monday to reclassify cannabis at the federal level. Right now, cannabis is a schedule one drug, same category as heroin. The executive order would drop it to schedule three in the same bucket as steroids and Tylenol with coding.Now, this is big. It means lower taxes, acces ...

Core Insights - IM Cannabis Corp. has appointed Asi Levi as the new Chief Financial Officer, effective immediately, replacing Uri Birenberg [1][3] - Asi Levi brings over 15 years of finance experience, having held CFO roles in various companies and expertise in fundraising, financial planning, and compliance with international financial reporting standards [2] Company Overview - IM Cannabis Corp. is a leading international cannabis company focused on providing premium cannabis products to medical patients in Israel and Germany, which are significant markets for medical cannabis [4] - The company aims for sustainable and profitable growth by leveraging a data-driven approach and a globally sourced product supply chain, while adhering to strict regulatory standards [4] - The IMC ecosystem includes subsidiaries in Israel that import and distribute cannabis, operate retail pharmacies, and manage logistics to ensure quality control and safe delivery of products [5]

Group 1: OKLO and Nuclear Power - Oklo Inc. Class A stock saw over 25% weekly gains after entering an ATM equity distribution agreement to issue up to $1.50 billion in common stock for financing its small modular reactor technology, particularly for AI data centers [1] Group 2: Natural Gas Market - The ProShares Ultra Bloomberg Natural Gas ETF (BOIL) gained more than 22% in the last week as U.S. natural gas prices surged to a three-year high due to intense winter cold and increasing export flows [2] Group 3: Cannabis Industry - The AdvisorShares MSOS Daily Leveraged ETF (MSOX) achieved approximately 21% weekly return, driven by a major acquisition announcement in Europe and positive sentiment regarding potential U.S. federal policy changes in the cannabis sector [3] Group 4: Palantir Technologies - Palantir Technologies' stock price increased significantly, supported by enthusiasm for its AI product suite and strong growth in both government and commercial sectors [4] Group 5: Semiconductor Sector - The Direxion Daily Semiconductor Bull 3x Shares (SOXL) recorded over 12% returns last week, benefiting from AI momentum and a stronger-than-expected decline in inflation expectations [5] Group 6: Quantum Computing - The Defiance Daily Target 2X Long IONQ ETF (IONX) was driven by renewed momentum in the quantum computing sector, with notable commentary from Nobel laureate John Martinis on China's advancements in this field [6] Group 7: Transportation Sector - The Direxion Daily Transportation Bull 3X Shares (TPOR) returned approximately 11.6% last week, fueled by optimism around stabilizing trade policies, improving freight rates, and strong e-commerce demand [7] Group 8: Tesla and AI Chips - The Direxion Daily TSLA Bull 2X Shares (TSLL) featured approximately 11% returns as Tesla's stock jumped following CEO Elon Musk's announcement about plans to manufacture AI chips at unprecedented volumes [8] Group 9: S&P 500 Performance - The Direxion Daily S&P 500 High Beta Bull 3X Shares (HIBL) provided 3x leveraged exposure to high-beta stocks, with the S&P 500 gaining due to investor expectations of an interest rate cut by the Federal Reserve and strong individual stock performances [9] Group 10: South Korean Market - The Direxion MSCI Daily South Korea Bull 3X Shares (KORU) saw significant performance due to global enthusiasm for AI and advanced chips, benefiting major companies like Samsung Electronics and SK Hynix [10]